Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB

Sarbassov, Dos D., Ali, Siraj M., Sengupta, Shomit, Sheen, Joon-Ho, Hsu, Peggy P., Bagley, Alex F., Markhard, Andrew L., Sabatini, David M.·2006·Molecular Cell
DOI 10.1016/j.molcel.2006.03.029

Cited by (128)

Items 101–128 of 128

  1. Translation Regulation as a Therapeutic Target in Cancer
    Grzmil, Michal, Hemmings, Brian A. · 2012 · Cancer Research
  2. Regulation of TOR by small GTPases
    Durán, Raúl V, Hall, Michael N · 2012 · The EMBO Reports
  3. TSC1/TSC2 signaling in the CNS
    Han, Juliette M., Sahin, Mustafa · 2011 · FEBS Letters
  4. mTOR kinase, a key player in the regulation of glial functions: Relevance for the therapy of multiple sclerosis
    Dello Russo, Cinzia, Lisi, Lucia, Feinstein, Douglas L., Navarra, Pierluigi · 2013 · Glia
  5. TOR kinase complexes and cell migration
    Liu, Lunhua, Parent, Carole A. · 2011 · Journal of Cell Biology
  6. mTOR-Dependent Cell Proliferation in the Brain
    Ryskalin, Larisa, Lazzeri, Gloria, Flaibani, Marina, Biagioni, Francesca, Gambardella, Stefano, Frati, Alessandro, Fornai, Francesco · 2017 · BioMed Research International
  7. mTORC Inhibitors as Broad-Spectrum Therapeutics for Age-Related Diseases
    Walters, Hannah E., Cox, Lynne S. · 2018 · International Journal of Molecular Sciences
  8. Fasting and rapamycin: diabetes versus benevolent glucose intolerance
    Blagosklonny, Mikhail V. · 2019 · Cell Death & Disease
  9. The role of the TOR pathway in mediating the link between nutrition and longevity
    Lushchak, Oleh, Strilbytska, Olha, Piskovatska, Veronika, Storey, Kenneth B., Koliada, Alexander, Vaiserman, Alexander · 2017 · Mechanisms of Ageing and Development
  10. Rapamycin-induced metabolic defects are reversible in both lean and obese mice
    Liu, Yuhong, Diaz, Vivian, Fernandez, Elizabeth, Strong, Randy, Ye, Lan, Baur, Joseph A., Lamming, Dudley W., Richardson, Arlan, Salmon, Adam B. · 2014 · Aging
  11. Rapamycin Increases Mortality in db/db Mice, a Mouse Model of Type 2 Diabetes
    Sataranatarajan, Kavithalakshmi, Ikeno, Yuji, Bokov, Alex, Feliers, Denis, Yalamanchili, Himabindu, Lee, Hak Joo, Mariappan, Meenalakshmi M., Tabatabai-Mir, Hooman, Diaz, Vivian, Prasad, Sanjay et al. · 2016 · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences
  12. mTOR regulates the expression of DNA damage response enzymes in long‐lived Snell dwarf, GHRKO, and PAPPA‐KO mice
    Dominick, Graham, Bowman, Jacqueline, Li, Xinna, Miller, Richard A., Garcia, Gonzalo G. · 2017 · Aging Cell
  13. Mammalian Target of Rapamycin (mTOR) Inhibitors: Potential Uses and a Review of Haematological Adverse Effects
    Sofroniadou, Sofia, Goldsmith, David · 2011 · Drug Safety
  14. mTORC2 (Rictor) in Alzheimer’s Disease and Reversal of Amyloid-β Expression-Induced Insulin Resistance and Toxicity in Rat Primary Cortical Neurons
    Lee, Han-Kyu, Kwon, Bumsup, Lemere, Cynthia A., de la Monte, Suzanne, Itamura, Kyohei, Ha, Austin Y., Querfurth, Henry W. · 2017 · Journal of Alzheimer's Disease
  15. Suppression of Hypoxia-Inducible Factor 1α (HIF-1α) by Tirapazamine Is Dependent on eIF2α Phosphorylation Rather Than the mTORC1/4E-BP1 Pathway
    Zhang, Jun, Cao, Ji, Weng, Qinjie, Wu, Rui, Yan, Yan, Jing, Hui, Zhu, Hong, He, Qiaojun, Yang, Bo · 2010 · PLoS ONE
  16. Potential therapeutic effects of the MTOR inhibitors for preventing ageing and progeria-related disorders
    Evangelisti, Camilla, Cenni, Vittoria, Lattanzi, Giovanna · 2016 · British Journal of Clinical Pharmacology
  17. Insulin-Like Growth Factor Signaling as a Therapeutic Target in Pancreatic Cancer
    Rieder, Simon, W. Michalski, Christoph, Friess, Helmut, Kleeff, > · 2011 · Anti-Cancer Agents in Medicinal Chemistry
  18. Therapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges
    Viana, Sofia D., Reis, Flávio, Alves, Rui · 2018 · Oxidative Medicine and Cellular Longevity
  19. Insulin Regulation of Hepatic Lipid Homeostasis
    Uehara, Kahealani, Santoleri, Dominic, Whitlock, Anna E. Garcia, Titchenell, Paul M. · 2023 · Comprehensive Physiology
  20. Rapamycin treatment dose‐dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC 1 and cell‐cycle‐associated CDK 1/cyclin axis
    Li, Ao, Fan, Song, Xu, Yuchen, Meng, Jialin, Shen, Xufeng, Mao, Jun, Zhang, Li, Zhang, Xiansheng, Moeckel, Gilbert, Wu, Dianqing et al. · 2017 · Journal of Cellular and Molecular Medicine
  21. Foxo3a is essential for maintenance of the hematopoietic stem cell pool.
    Miyamoto, Kana, Araki, Kiyomi Y., Naka, Kazuhito, Arai, Fumio, Takubo, Keiyo, Yamazaki, Satoshi, Matsuoka, Sahoko, Miyamoto, Takeshi, Ito, Keisuke, Ohmura, Masako et al. · 2007 · Cell stem cell
  22. Tim-3 adaptor protein Bat3 is a molecular checkpoint of T cell terminal differentiation and exhaustion
    Zhu, Chen, Dixon, Karen O., Newcomer, Kathleen, Gu, Guangxiang, Xiao, Sheng, Zaghouani, Sarah, Schramm, Markus A., Wang, Chao, Zhang, Huiyuan, Goto, Kouichiro et al. · 2021 · Science Advances
  23. Mechanistic Target of Rapamycin Complex 1 Signaling Modulates Vascular Endothelial Function Through Reactive Oxygen Species
    Reho, John J., Guo, Deng‐Fu, Rahmouni, Kamal · 2019 · Journal of the American Heart Association
  24. Lack of muscle mTOR kinase activity causes early onset myopathy and compromises whole‐body homeostasis
    Zhang, Qing, Duplany, Agnès, Moncollin, Vincent, Mouradian, Sandrine, Goillot, Evelyne, Mazelin, Laetitia, Gauthier, Karine, Streichenberger, Nathalie, Angleraux, Céline, Chen, Jie et al. · 2019 · Journal of Cachexia, Sarcopenia and Muscle
  25. AKT/mTORC pathway in antiphospholipid-related vasculopathy: a new player in the game
    Canaud, G, Legendre, C, Terzi, F · 2015 · Lupus
  26. Tuberous sclerosis complex–associated CNS abnormalities depend on hyperactivation of mTORC1 and Akt
    Zordan, Paola, Cominelli, Manuela, Cascino, Federica, Tratta, Elisa, Poliani, Pietro L., Galli, Rossella · 2018 · Journal of Clinical Investigation
  27. A targeted approach to phosphoinositide-3-kinase/Akt/mammalian target of rapamycin-induced hyperglycemia
    Cheung, Yee-Ming Melody, McDonnell, Marie, Hamnvik, Ole-Petter Riksfjord · 2022 · Current Problems in Cancer
  28. Pre-existing Cell States Control Heterogeneity of Both EGFR and CXCR4 Signaling
    Spinosa, Phillip C., Kinnunen, Patrick C., Humphries, Brock A., Luker, Gary D., Luker, Kathryn E., Linderman, Jennifer J. · 2021 · Cellular and Molecular Bioengineering